ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.…
ICON: 3 Key Takeaways for Long-Term Investors
ICON (NASDAQ: ICLR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 40,250 employees.
The shares were at 186.71 USD on 20 November 2026, up 14.3% over 52 weeks. Its 52-week range is 66.57 USD to 219.00 USD: the price is 14.7% below the high and 180.5% above the low.
At a market capitalisation of 13.99B USD, it trades at 74.7 times trailing earnings and 16.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 33.8, a premium of 121% for ICLR.
ICON reports return on equity of 2.5%, an operating margin of 2.7% and revenue down 2.9% year over year.
Its debt exceeds its cash by 2.70B USD, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 231.29 USD is 23.9% above the current price. The next earnings report is expected on 17 February 2027.